Lenz Robert A. 4
4 · LB PHARMACEUTICALS INC · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
LBRX Director Robert Lenz Receives 12,500-Share Award
What Happened Robert A. Lenz, a director of LB Pharmaceuticals, was granted a derivative award for 12,500 shares on June 3, 2026. The filing reports an acquisition at $0.00 (no cash paid). The award includes an option component (see footnotes) and was reported on an SEC Form 4 filed June 5, 2026.
Key Details
- Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
- Transaction type: Grant / award (derivative), 12,500 shares acquired at $0.00.
- Footnote F1: 2,500 of the shares are an option award under the issuer’s non-employee director compensation policy (prorated annual grant).
- Footnote F2: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the issuer’s next annual meeting, subject to continuous service through vesting.
- Shares owned after the transaction: not disclosed in the filing.
Context This was an award of derivative securities rather than an open-market purchase or sale. The option portion has a time-based vesting condition; no immediate sale or cashless exercise is indicated. Awards to non-employee directors are a routine part of compensation and do not, by themselves, indicate a buying or selling signal.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-06-03+12,500→ 12,500 totalExercise: $27.95Exp: 2036-06-02→ Common Stock (12,500 underlying)
Footnotes (2)
- [F1]Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year.
- [F2]100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.